The latest report by IMARC Group, titled “Erythropoietin Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“. The global erythropoietin drugs market size reached US$ 10.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 14.5 Billion by 2028, exhibiting a growth rate (CAGR) of 5.65% during 2023-2028.

Erythropoietin drugs, or EPO drugs, are medications that mimic the action of a natural hormone called erythropoietin. It is primarily produced by the kidneys and is essential in regulating the production of red blood cells (RBCs) in the body. These drugs are used in medical settings to treat conditions characterized by anemia or low red blood cell count. It works by stimulating the bone marrow to generate more red blood cells, thus increasing the oxygen-carrying capacity of the blood, which is beneficial for individuals with chronic kidney disease, cancer patients undergoing chemotherapy, and those with certain types of anemia. Additionally, EPO drugs are carefully monitored by healthcare professionals, as improper or excessive administration can lead to harmful effects, including high blood pressure and an increased risk of blood clots.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/erythropoietin-drugs-market/requestsample

Erythropoietin Drugs Market Trends and Drivers:

The erythropoietin drugs market is primarily driven by the rising incidence of anemia. In addition, anemia is a medical condition characterized by a deficiency of RBCs or hemoglobin in the blood, leading to the adoption of erythropoietin drugs for the treatment of anemia, particularly in patients with chronic kidney disease, cancer patients undergoing chemotherapy, and those with human immunodeficiency virus infection (HIV) and acquired immune deficiency syndrome (AIDS), influencing the market growth. Moreover, ongoing research in the field of erythropoietin drugs is expanding their potential applications, representing another major growth-inducing factor. Besides this, the increasing use of erythropoietin drugs in various medical conditions, such as myelodysplastic syndromes, which are a group of disorders affecting blood and bone marrow, is accelerating market growth. Also, EPO drugs are used in pre-operative preparations for certain surgical procedures to increase red blood cell count. Along with this, pharmaceutical companies are continually innovating and introducing new formulations and delivery methods for erythropoietin drugs, making them convenient for patients and leading to higher product adoption rates. Furthermore, the implementation of favorable reimbursement policies in various countries to make these treatments more affordable for patients is creating a positive market outlook.

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Drug Class:

  • Biologics
  • Biosimilars

Breakup by Product Type:

  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin-alfa
  • Others

Breakup by Application:

  • Hematology
  • Kidney Disorder
  • Cancer
  • Others

Breakup by End User:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Market Breakup by Region:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

Competitive Landscape with Key Player:

  • Amgen Inc.
  • Biocon Limited
  • Dr. Reddy’s Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • LG Chem Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

Email: sales@imarcgroup.com

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Address: 134 N 4th St. Brooklyn, NY 11249, USA

Follow us on Twitter: @imarcglobal